Association of CYP1B1 Haplotypes and Breast Cancer Risk in Caucasian Women
- Yifan Huang1,
- Amy Trentham-Dietz3,4,
- Montserrat García-Closas5,
- Polly A. Newcomb3,6,
- Linda Titus-Ernstoff7,
- John M. Hampton4,
- Stephen J. Chanock5,
- Jonathan L. Haines8 and
- Kathleen M. Egan2
- 1Biostatistics Core and 2Department of Cancer Prevention and Control, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; 3Department of Population Health Sciences, University of Wisconsin-Madison and 4University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 6Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington; 7Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, New Hampshire; and 8Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, Tennessee
- Requests for reprints:
Kathleen Egan, H. Lee Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL 33612. Phone: 813-745-6803; Fax: 813-745-6525. E-mail: Kathleen.Egan{at}Moffitt.org
Abstract
CYP1B1 is a key enzyme involved in estrogen metabolism and may play an important role in the development and progression of breast cancer. In a population-based case-control study, we examined eight CYP1B1 haplotype-tagging single nucleotide polymorphisms in relation to invasive breast cancer risk. Analyses were based on 1,655 cases and 1,470 controls; all women were Caucasian. Among the individual single nucleotide polymorphisms, one (rs9341266) was associated with increased risk of breast cancer (Ptrend = 0.021), although the association was no longer significant after adjusting for multiple tests. A marginally significant haplotype effect was identified (Pglobal = 0.015), with significant associations identified for 2 uncommon haplotypes comprising 4% of the controls. Results suggest that genetic variation in CYP1B1 has at most a minor influence on breast cancer susceptibility among Caucasian women. (Cancer Epidemiol Biomarkers Prev 2009;18(4):1321–3)
Footnotes
-
- Accepted February 9, 2009.
- Received September 11, 2008.
- Revision received January 20, 2009.
